论文部分内容阅读
目的:观察胸腺素联合化疗治疗耐多药肺结核的临床疗效。方法:选择耐多药肺结核175例,随机分为观察组88例和对照组87例。对照组以力克肺疾、左氧氟沙星为基础,与2或3种可供配伍的抗结核药物组成抗结核方案,疗程18个月;观察组在上述治疗基础上加用胸腺素治疗。结果:观察组治疗6个月痰菌阴转71例(80.6%),对照组痰菌阴转48例(55.2%),两组比较,差异显著(P<0.05);观察组治疗18个月空洞闭合率73.9%、治疗有效率82.9%,显著高于对照组的55.2%和66.7%,两组比较,差异显著(P<0.05);治疗后观察组CD3、CD4及CD4/CD8水平均显著上升,与对照组比较,差异非常显著(P<0.01)。结论:胸腺素联合化疗治疗耐多药肺结核临床疗效较好。
Objective: To observe the clinical efficacy of thymosin combined with chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis. Methods: 175 cases of MDR-TB were selected and randomly divided into observation group (88 cases) and control group (87 cases). Control group to Lectra lung disease, levofloxacin-based, with 2 or 3 types of anti-TB drugs for compatibility anti-TB program, course of treatment 18 months; the observation group in the treatment based on the use of thymosin treatment. Results: In the observation group, 71 cases (80.6%) had sputum negative conversion in 6 months and 48 cases (55.2%) in the control group, the difference was significant (P <0.05); the observation group was 18 months The void closure rate was 73.9%, and the effective rate of treatment was 82.9%, which was significantly higher than that of the control group (55.2% and 66.7%, P <0.05). After treatment, the levels of CD3, CD4 and CD4 / CD8 in the observation group were significantly Rise, compared with the control group, the difference was significant (P <0.01). Conclusion: Thymosin combined with chemotherapy is effective in treating multi-drug resistant pulmonary tuberculosis.